Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma Inc (NQ: INZY )

4.720 +0.120 (+2.61%)
Streaming Delayed Price Updated: 1:31 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 162,260
Open 4.650
Bid (Size) 4.710 (1)
Ask (Size) 4.730 (3)
Prev. Close 4.600
Today's Range 4.600 - 4.720
52wk Range 2.689 - 7.795
Shares Outstanding 61,729,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+9.01%
+9.01%
1 Month
+4.66%
+4.66%
3 Month
-18.34%
-18.34%
6 Month
+21.03%
+21.03%
1 Year
-29.97%
-29.97%

More News

Read More
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma: Q4 Earnings Insights
Via Benzinga
6 Analysts Have This to Say About Inozyme Pharma
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
Via Benzinga
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
Via Benzinga
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From Inozyme Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.